| MeSH term | MeSH ID | Detail |
|---|---|---|
| Insulin Resistance | D007333 | 99 associated lipids |
| Weight Gain | D015430 | 101 associated lipids |
| Glioma | D005910 | 112 associated lipids |
| Hypertension | D006973 | 115 associated lipids |
| Inflammation | D007249 | 119 associated lipids |
| Cell Transformation, Neoplastic | D002471 | 126 associated lipids |
| Hemolysis | D006461 | 131 associated lipids |
| Carcinoma, Hepatocellular | D006528 | 140 associated lipids |
| Edema | D004487 | 152 associated lipids |
| Colonic Neoplasms | D003110 | 161 associated lipids |
| Adenocarcinoma | D000230 | 166 associated lipids |
| Lung Neoplasms | D008175 | 171 associated lipids |
| Body Weight | D001835 | 333 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Srinivas NR | Letter: sublingual dosing of tacrolimus in transplant patients-interesting concept to overcome first pass effects. | 2017 | Aliment. Pharmacol. Ther. | pmid:28589592 |
| BenÃtez C et al. | Letter: sublingual dosing of tacrolimus in transplant patients-interesting concept to overcome first pass effects. Authors' reply. | 2017 | Aliment. Pharmacol. Ther. | pmid:28589580 |
| Romano C et al. | Oral tacrolimus (FK 506) in refractory paediatric ulcerative colitis. | 2010 | Aliment. Pharmacol. Ther. | pmid:20148798 |
| Itoh S et al. | Inhibition of CN (protein phosphatase-2B) suppresses Ca2+-mediated acid secretion in rats. | 2002 | Aliment. Pharmacol. Ther. | pmid:11966520 |
| Yamamoto S et al. | Long-term effect of tacrolimus therapy in patients with refractory ulcerative colitis. | 2008 | Aliment. Pharmacol. Ther. | pmid:18549460 |
| O'Leary JG | Editorial: tacrolimus-how low can you go? | 2017 | Aliment. Pharmacol. Ther. | pmid:28589579 |
| Firpi RJ et al. | Sirolimus-induced hyperlipidaemia in liver transplant recipients is not dose-dependent. | 2004 | Aliment. Pharmacol. Ther. | pmid:15113371 |
| Herrlinger KR et al. | Infliximab as rescue medication for patients with severe ulcerative/indeterminate colitis refractory to tacrolimus. | 2010 | Aliment. Pharmacol. Ther. | pmid:20175769 |
| Solari S et al. | Sublingual tacrolimus administration provides similar drug exposure to per-oral route employing lower doses in liver transplantation: a pilot study. | 2017 | Aliment. Pharmacol. Ther. | pmid:28261844 |
| Schwrer H et al. | Pantoprazole and cyclosporine or tacrolimus. | 2001 | Aliment. Pharmacol. Ther. | pmid:11284790 |
| Högenauer C et al. | Effect of oral tacrolimus (FK 506) on steroid-refractory moderate/severe ulcerative colitis. | 2003 | Aliment. Pharmacol. Ther. | pmid:12940927 |
| Trotter JF et al. | Effect of hepatitis C infection on tacrolimus doses and blood levels in liver transplantation recipients. | 2005 | Aliment. Pharmacol. Ther. | pmid:15963078 |
| Hoshino H et al. | Effects of FK506 on an experimental model of colitis in rats. | 1995 | Aliment. Pharmacol. Ther. | pmid:7544633 |
| Lawrance IC and Copeland TS | Rectal tacrolimus in the treatment of resistant ulcerative proctitis. | 2008 | Aliment. Pharmacol. Ther. | pmid:18761706 |
| Liberal R et al. | Expert clinical management of autoimmune hepatitis in the real world. | 2017 | Aliment. Pharmacol. Ther. | pmid:28004405 |
| Segal JP et al. | Systematic review with meta-analysis: the management of chronic refractory pouchitis with an evidence-based treatment algorithm. | 2017 | Aliment. Pharmacol. Ther. | pmid:28008631 |
| Yamamoto T et al. | Editorial: tacrolimus vs. anti-tumour necrosis factor agents for moderately to severely active ulcerative colitis--authors' reply. | 2016 | Aliment. Pharmacol. Ther. | pmid:27040167 |
| Taylor KM and Sparrow MP | Editorial: tacrolimus vs. anti-tumour necrosis factor agents for moderately to severely active ulcerative colitis. | 2016 | Aliment. Pharmacol. Ther. | pmid:27040166 |
| Haagsma EB et al. | Inflammatory bowel disease after liver transplantation: the effect of different immunosuppressive regimens. | 2003 | Aliment. Pharmacol. Ther. | pmid:12848624 |
| Nakase H et al. | Cytomegalovirus affects clinical outcome of infliximab in ulcerative colitis refractory to tacrolimus. | 2010 | Aliment. Pharmacol. Ther. | pmid:20636704 |